Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 5Unknown 3Recruiting 2Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 264Osteosarcoma 80Sarcoma, Ewing 50Neoplasms 43Melanoma 43Gastrointestinal Stromal Tumors 41Colorectal Neoplasms 39Breast Neoplasms 37Bone Neoplasms 36Rhabdomyosarcoma 35Neoplasm Metastasis 32Ovarian Neoplasms 31Neuroblastoma 30Pancreatic Neoplasms 29Stomach Neoplasms 27Dendritic Cell Sarcoma, Interdigitating 27Lung Neoplasms 26Liposarcoma 26Leiomyosarcoma 25Glioblastoma 23Uterine Cervical Neoplasms 22Sarcoma, Synovial 22Head and Neck Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Esophageal Neoplasms 21Sarcoma, Kaposi 18Lymphoma 18Carcinoma, Hepatocellular 18Urinary Bladder Neoplasms 17Prostatic Neoplasms 17

Interventions

olverembatinib 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × GIST × Sarcoma × Clear all
NCT07096609 2026-04-03

LONGIST

Asan Medical Center

Phase 1/2 Recruiting
48 enrolled
Sarcoma

GIST

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting
40 enrolled
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡